TORONTO, ONTARIO--(Marketwired - March 30, 2017) - Microbix Biosystems Inc. (TSX:MBX) (“Microbix” or the “Company”), an innovator of biological products and technologies, announces the results of the Annual Meeting of Shareholders which was held on March 29, 2017, at which 37.07% of the issued and outstanding shares were represented. Shareholders voted in favour of all resolutions brought before the meeting. A detailed description of all resolutions that were voted on can be reviewed in the Company’s Information Circular which was filed on SEDAR on February 22, 2017. All of the director nominees listed in the Information Circular were re-elected as directors of Microbix. Detailed results of the vote are set out below:
| For | % For | Withheld | % Withheld | |
| Peter M. Blecher | 25,717,078 | 91.22 | 2,475,018 | 8.78 |
| William J. Gastle | 27,638,648 | 98.04 | 553,448 | 1.96 |
| Martin Marino | 25,221,078 | 89.46 | 2,971,018 | 10.54 |
| Joseph D. Renner | 27,257,894 | 96.69 | 934,202 | 3.31 |
| Mark A. Cochran | 25,741,578 | 91.31 | 2,450,518 | 8.69 |
| Cameron Groome | 26,318,943 | 93.36 | 1,873,153 | 6.64 |
| Vaughn C. Embro-Pantalony | 27,034,562 | 95.89 | 1,157,534 | 4.11 |
In addition, shareholders also approved a resolution appointing the Company’s auditors, Ernst & Young LLP with 99.01% of the votes cast in favour.
About Microbix Biosystems
Microbix Biosystems Inc. specializes in the research, development, marketing and distribution of biological solutions. This includes products for human health applications in the vaccine, therapeutic and diagnostic markets, in addition to a product for the worldwide animal reproduction market. In its revenue generating business, the Company manufactures and distributes a wide range of infectious disease antigens to a worldwide customer base. The Company is also developing a pipeline of innovative technologies and product candidates, including LumiSort semen sexing technology for the livestock industries and Kinlytic, a thrombolytic drug with several approved and potential applications, including the treatment of life-threatening blood clots. Established in 1988, Microbix is a publicly traded company, listed on the Toronto Stock Exchange, and headquartered in Mississauga, Ontario.
Please visit www.sedar.com for recent Microbix Biosystems Inc. filings.
For further information, please visit www.microbix.com.